CanSino Biologics Inc. (6185.HK)
HKD 33.5
(-1.33%)
HKD 33.5
(-1.33%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.64 Billion CNY | -64.07% |
| 2022 | -1.02 Billion CNY | -152.06% |
| 2021 | 1.97 Billion CNY | 590.61% |
| 2020 | -402.96 Million CNY | -192.11% |
| 2019 | -204.89 Million CNY | 0.62% |
| 2018 | -126.26 Million CNY | -104.82% |
| 2017 | -67.76 Million CNY | -50.17% |
| 2016 | -45.12 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 14.18 Million CNY | 109.91% |
| 2024 Q1 | -143.06 Million CNY | 89.51% |
| 2023 Q2 | -1.09 Billion CNY | -487.31% |
| 2023 Q1 | -185.99 Million CNY | 83.59% |
| 2023 FY | - CNY | -64.07% |
| 2023 Q4 | -1.36 Billion CNY | -299.19% |
| 2023 Q3 | 684.71 Million CNY | 162.68% |
| 2022 Q3 | -36.01 Million CNY | 87.19% |
| 2022 Q4 | -1.13 Billion CNY | -3046.6% |
| 2022 Q1 | 129.25 Million CNY | -79.33% |
| 2022 Q2 | -281.03 Million CNY | -317.42% |
| 2022 FY | - CNY | -152.06% |
| 2021 Q4 | 625.41 Million CNY | 56.56% |
| 2021 FY | - CNY | 590.61% |
| 2021 Q1 | -43.86 Million CNY | 85.81% |
| 2021 Q3 | 399.48 Million CNY | -52.48% |
| 2021 Q2 | 840.72 Million CNY | 2016.84% |
| 2020 Q3 | -75.43 Million CNY | -27.99% |
| 2020 FY | - CNY | -192.11% |
| 2020 Q2 | -58.94 Million CNY | -67.8% |
| 2020 Q1 | -35.12 Million CNY | -66.38% |
| 2020 Q4 | -309.17 Million CNY | -309.86% |
| 2019 Q3 | -40.95 Million CNY | -134.37% |
| 2019 FY | - CNY | 0.62% |
| 2019 Q2 | -17.47 Million CNY | 61.98% |
| 2019 Q1 | -45.96 Million CNY | -7.91% |
| 2019 Q4 | -21.11 Million CNY | 48.45% |
| 2018 Q1 | -26.98 Million CNY | 14.51% |
| 2018 Q3 | -42.59 Million CNY | -57.84% |
| 2018 Q4 | -42.59 Million CNY | 0.0% |
| 2018 FY | - CNY | -104.82% |
| 2018 Q2 | -26.98 Million CNY | 0.0% |
| 2017 Q2 | -13.99 Million CNY | 0.0% |
| 2017 Q4 | -31.56 Million CNY | 0.0% |
| 2017 FY | - CNY | -50.17% |
| 2017 Q1 | -13.99 Million CNY | 0.0% |
| 2016 Q1 | -10.86 Million CNY | 0.0% |
| 2016 FY | - CNY | 0.0% |
| 2016 Q4 | -13.99 Million CNY | 0.0% |
| 2016 Q2 | -10.86 Million CNY | 0.0% |
| 2015 Q4 | -10.86 Million CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | 1194.206% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | 155.475% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | -1170.604% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | 1546.147% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | -3176.366% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | 1598.53% |
| Essex Bio-Technology Limited | 418.37 Million HKD | 493.35% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | 2247.49% |
| PuraPharm Corporation Limited | -26.16 Million HKD | -6188.685% |
| SSY Group Limited | 2.11 Billion HKD | 177.827% |
| JBM (Healthcare) Limited | 204.39 Million HKD | 905.17% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | 482.788% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 110.665% |